Adrian Johnson

TLDR: CDIB Capital Group and Cool Japan Fund have launched a $62m joint fund to build a startup ecosystem between Japan and Taiwan. The CDIB Cross Border Innovation Fund will focus on

TLDR: VCs struggle to predict successful ventures, with most investments failing. Entrepreneurs can outsmart VCs by focusing on evidence, proving their strategy, and retaining control. Dileep Rao’s article discusses how smart entrepreneurs

TLDR: Claudio Lambert rejoined Rendimento Ventures as head after a five-month stint at a financial advisory group. Rendimento Ventures focuses on seed to series A-stage business-to-business financial technology startups that are generating

TLDR: Private equity and venture capital are becoming more popular in retirement portfolios due to higher potential returns. There are seven strategies to consider when incorporating private equity into your retirement portfolio.

TLDR: European BDB deeptech VC firm UVC Partners has closed its fourth fund at €250 million. The fund, UVC IV, was launched just six months ago. European BDB deeptech VC firm UVC

TLDR: Neobanks in Europe are experiencing increased profits due to significant VC investment. Focus on profitability, diversifying product offerings, and strategic expansion driving growth. In recent years, neobanks have been disrupting the

TLDR: Data centers have been driving a lot of private equity deals this year. Foresight is focusing on energy transition opportunities, while Lightyear Capital is supporting mental health in the workforce. In

TLDR: RevTech Labs Capital, a Charlotte-based venture capital firm, has gained national recognition for its investments in fintech startups. The firm’s commitment to accelerator programs, leadership training, and investments ranging from $200,000

TLDR: Blockchain VC spending rose to $2.7 billion in Q2 of 2024, with layer-2 blockchains and infrastructure projects gaining traction. Some VCs are cooling on artificial intelligence. Ethereum layer-2 scaling seen as

TLDR: Key Points: Central New York lacks the density and range of capital sources found in tech hubs like Silicon Valley. A new biotech venture fund called Upstate Biotech Ventures is being